| Description: |
Phenytoin is an anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
Phenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Phenytoin reduces the maximal activity of brain stem centres responsible for the tonic phase of tonic-clonic (grand mal) seizures. Phenytoin acts to damp the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells. It lacks the sedation effects associated with phenobarbital. There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA. Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient.
|
| Application:
|
The antibody is suitable for the development of immunoassays or immunoaffinity purification
columns.
|
| Buffer:
|
20mM Phosphate, 150mM Sodium Chloride, pH 7.2
|
| Footer:
|
For in vitro use only, research applications not intended for diagnostic or therapeutic purposes
|
| Format:
|
Ig fraction
|
| Host:
|
Sheep
|
| Ig Con:
|
9.63 mg/ml (U.V. abs at 280nm)
|
| Immunogen:
|
Phenytoin-BTG
|
| Lot:
|
RS1318-03
|
| Preservative:
|
0.09% Sodium Azide
|
| Related:
|
Phenytoin -HRP Cat. No. HRP9418, size 0.5 ml
|
| Sensitivity:
|
10 ng/ml phenytoin produces 83% inhibition in
a competitive ELISA, employing phenytoin
polyclonal antibody.
|
| Specificity:
|
Data not yet available.
|
| Storage:
|
≤ -20C, avoid repeated freeze/thaw cycles
|
| Work Con:
|
1.25 μg/ml (ELISA microtitre platebased)
|
| References:
|
1. Abou-Khalil B, Ge Q, Desai R, Ryther R, Bazyk A, Bailey R, Haines JL, Sutcliffe JS, George AL Jr: “Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation”. Neurology. 2001 Dec 26;57(12):2265-7
2. Lu CM, Han J, Rado TA, Brown GB: “Differential expression of two sodium channel subtypes in human brain”. FEBS Lett. 1992 May 25; 303(1):53-8.
3. Malo MS, Blanchard BJ, Andresen JM, Srivastava K, Chen XN, Li X, Jabs EW, Korenberg JR, Ingram VM: “Localization of a putative human brain sodium channel gene (SCN1A) to chromosome band”. Cytogenet Cell Genet. 1994;67(3):178-86
|
| Datasheet: |
|
